SELL and autoimmune disease: These ex vivo expanded, highly enriched Th-2+CD62L+CD4+iNKT cells may have a tremendous potential as novel cell therapeutics for several autoimmune diseases where quantitative and qualitative defects of iNKT cells are linked to the pathogenesis of the disease (65–67).